- Biomarkers in amyotrophic lateral sclerosis: opportunities and limitationsRobert Bowser
Division of Neurology, Barrow Neurological Institute, St Joseph s Hospital and Medical Center, 350 West Thomas Street, Phoenix, AZ 85213, USA
Nat Rev Neurol 7:631-8. 2011..The ultimate aim is to broaden the therapeutic options for patients with this disease...
- A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease ProgressionTodd D Levine
Phoenix Neurological Associates, 5090 N 40th Street Suite 250, Phoenix, AZ 85018, USA
Neurol Res Int 2012:582075. 2012..ALS patients who were treated with tretinoin and pioglitazone demonstrated no slowing on their disease progression. Interestingly, the rate of disease progression was strongly correlated with levels of pNFH in the CSF at baseline...
- A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkersTodd D Levine
PNA Center for Neurologic Research, 5090 N 40th St, Phoenix, AZ 85018, USA
Amyotroph Lateral Scler 11:514-9. 2010..Patients receiving memantine and riluzole lost on average -0.73 ALSFRS points per month. Furthermore, levels of CSF tau at baseline could be correlated with how rapidly a patient's disease progressed...